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Objective. Diagnostic reliability of prenephroureterectomy ureteroscopy (PNU) for the detection of upper tract carcinoma in situ
(CIS) remains unproven in particular and underreported in general.Methods. Patients who underwent radical nephroureterectomy
(RNU) in a large multicentre retrospective study for upper tract transitional cell carcinoma (UT-TCC) between January 2002 and
December 2013 were identified from our hospitals databases. PNU appearances, stage, and grade of ureteroscopic biopsy were
compared with final histology results of RNU to assess the diagnostic reliability of PNU for carcinoma in situ (CIS). Results. Three
hundred patients underwent RNU for UT-TCC. 106 (106/300; 35.3%) of the cohort had PNU using white light with biopsies taken
in most (92/106; 86.7%). Postnephroureterectomy histology of the cohort showed CIS in 65 (65/300; 21.6%) patients.Thirty nine of
patients with CIS (39/65; 60%) had prenephroureterectomy ureteroscopy biopsies. Out of ten patients with CIS on ureteroscopic
biopsies, six did not show CIS on final histopathology (6/10; 60%). Moreover, grading and staging on PNU biopsies of obvious
tumours showed a significant nonconcordance with final histopathology of RNU specimen (𝑃 = 0.02). Overall survival was also
shorter in patients with CIS compared with those without; this showed strong statistical significance (𝑃 = 0.004). Conclusions.
There is a high incidence of CIS in upper tract with significant underdetection and discordance rate between the histopathology of
biopsy samples obtained by white light PNU and resected specimen of radical nephroureterectomy. The presence of concomitant
CIS and high stage disease in the upper tract TCC carried a poor prognosis following radical nephroureterectomy.
1. Introduction
Upper tract urothelial cell carcinoma (UT-UCC) accounts
for approximately 5% of all urothelial cancers with an inci-
dence of 1-2 per 100,000 population/year [1]. The clinical
diagnosis of these cancers is made on upper tract imaging
(CT urography), urine cytology, and ureteroscopic biopsy.
Accurate grading and staging using these modalities form
the cornerstone for risk stratifying patients to appropriate
treatment options including endoscopic management.
Radical nephroureterectomy (RNU) with excision of cuff
of urinary bladder on the tumour bearing side remains the
standard-of-care for high grade and high stage disease.There
are, however, an increasing number of reports of endoscopic
nephron-sparing approaches, particularly in small and low
grade tumours [2–5].Weighing the advantages of endoscopic
nephron-sparing approaches against oncological failure is
crucial and perhaps the most challenging. The recent EAU
guidelines suggest endoscopic nephron-sparing approaches
(eNSS) asmanagement options for low grade and low volume
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disease even in healthy fit patients with normal contralateral
kidneys [6]. Grade and stage of tumours are the major
determinants of oncological outcomes and this important
information on prenephroureterectomy ureteroscopy (PNU)
biopsy is critical for selecting patients for safe endoscopic
approaches [7].
Presence of concomitant carcinoma in situ (CIS) on
PNU could potentially influence decision making as CIS
is considered to be a poor prognostic histologic feature in
contemporary bladder cancer series [8]. There is a paucity
of the reported literature for incidence of carcinoma in
situ in upper tract, diagnosis by PNU, and/or suspecting
these lesions on abnormal mucosal appearances during
ureteroscopy. Nevertheless, its presence in the postresec-
tion final nephroureterectomy specimen is associated with
increased disease recurrences and progression. Almost one in
three patients following RNUwas found to have concomitant
CIS in a single-institutional study [9] with significant impact
on follow-up recurrences. This has been further confirmed
by recent reports [10, 11]. McCarron Jr. et al. reported a
higher incidence of CIS in close proximity to the obvious
tumours [12]. Therefore, the presence of a concomitant CIS
should always be actively sought in patients with UT-UUC,
in particularly those opting for endoscopic management.
There are, however, a number of recognised concerns: limited
diagnostic accuracy of white light endoscopy for subtle and
early mucosal changes, no protocols for random biopsies,
no reliable technique of using photosensitizers for photo-
dynamic diagnosis in upper tract, and discrepancy between
PNU biopsy and final radical nephroureterectomy histology
and poor yield of PNU biopsy specimen to reliable grade and
stage disease.These unresolved issues impede the progress of
endoscopic management in UT-UCC.
The aims of the present study are as follows:
(1) to report incidence of concomitant CIS in radical
nephroureterectomy and assess reliability of white
light PNU with biopsy in diagnosing these lesions,
(2) to evaluate the impact of concomitant CIS on the
oncological outcomes (recurrence-free survival and
disease specific and overall survival) of patients with
UT-UCC.
2. Patients and Methods
2.1. Data Source. SUrgical Treatment of Upper tRact urothe-
lial cancErs (SUTURE) group is a large consortium of sur-
geons with specific interest in the outcomes of UT-TCC. The
hospitals of consortium membership cater a relatively stable
population of more than 1.5 million of the UK. Histology
of each patient is reviewed at local weekly multidisciplinary
meetings by uropathologists and the outcome is safely stored
in pass word protected computers.
We identified a cohort of patients who underwent
RNU for clinically localised UT-UCC between January 2000
and December 2013 using terms “nephroureterectomy” and
“ureteroscopy” in cancer multidisciplinary meetings records.
The numbers were validated by cross-checking databases
maintained independently by the department of pathology
of the institutions. Extracted data comprised ten-digit unique
community health index number (CHI number for Scotland
alone), anonymised date of birth, presenting symptoms,
imaging investigations, notes from multidisciplinary meet-
ings, PNU biopsy results, date of surgery, histopathology of
the radical surgery, recurrences, and finally the date of death
along with underlying and contributory cause of death.
Staging of tumours by TNM system and grade of tumour
differentiation according to WHO classification of 1998 [13]
were extracted from the histopathology andmultidisciplinary
records and classified into three tier-numbering categories:
(1) G1—low grade, (2) G2—intermediate grade, and (3) G3—
high grade [14, 15]. All surgical procedures were performed
either by employing laparoscopic or open approaches. Voided
urinary cytology specimens were obtained prior to any
instrumentations/procedures for the detection of malignant
cells.The specimen were immediately sent to pathology labo-
ratory and examined by senior cytologists using conventional
methods.
2.2. PNU and Ureteroscopic Biopsy Technique. The tech-
nique of ureterorenoscopy has been described previously
[16]. The consortium members have a special interest in
this area including use of photosensitizer in the upper
tract [16]. In order to rule out possibility of CIS, normal
looking mucosa was not biopsied to rule out the possi-
bility of CIS. Briefly, following standard cystoscopy, white
light ureterorenoscopy (semirigid and flexible; 7.5 Fr KARL
STORZFlex-X ureterorenoscope) was carried out to visualize
tumors suspected or seen on imaging. A 3-Fr Piranha (Boston
Scientific, Natick, MA, USA) cold cup forceps were intro-
duced through the ureteroscope and surface of the lesions
was grasped. The grasped tissue is pulled out along with the
ureteroscopes.On fewoccasions stone baskets (Boston Scien-
tific,Natick,MA,USA) or 3 Fr biopsy forceps (KARL STORZ,
Germany) or brush forceps were used instead. Multiple biop-
sies were carried out from all obvious or suspicious areas or
both. Randombiopsies fromnormalmucosawere taken from
upper urinary tract only if they were reported as suspicious
(thickening of ureter, etc.) on CT urogram. The biopsy
specimen were fixed in formalin and processed as standard
for haematoxylin and eosin staining. The WHO histological
grading system was used as described above. All patients
in the present study had confirmed diagnosis of upper UT-
UC on final histopathology. Radical nephroureterectomy
procedures were performed by a standard open approach
or transperitoneal laparoscopic route with handling of the
lower end of the ureter either endoscopically or by an open
method. In most of tumors in the lower end of ureter, open
excision was performed except for a selected group where
wide excision of cuff of bladderwas carried out by a technique
described by our group [17].
2.3. Follow-Up Protocol. Patients were followed up according
to standard protocols at each centre. Follow-up consisted of
a history, physical examination, routine blood work, urinary
cytology, and flexible cystoscopic inspection of the urinary
bladder. Cystoscopy was performed at 3–5 months following
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nephroureterectomy and annually thereafter. Cross-sectional
imaging (abdominal and chest computed tomography or
magnetic resonance imaging) was performed at 6 months
after surgery and yearly thereafter. Any recurrences were
brought back to the multidisciplinary meetings for review of
management plans.
2.4. Oncological Outcomes. Recurrence was defined as a new
urothelial cancer in the bladder/urethra (lower urinary tract
recurrence), contralateral upper tract, or local recurrence.
Metastasis was recorded separately.
The primary outcome of the study was a diagnostic
accuracy of PNU in reliably diagnosing concomitant CIS and
the secondary outcome was recurrence-free, cancer specific,
and overall survival in men with concomitant CIS in upper
tract.
2.5. Statistical Analysis. The impact of PNU on the detection
of CIS was described as a number of patients and percentages
for all categorical variables. The Fisher’s exact test and the
two-tailed test were used to evaluate the association between
PNU (detection of CIS, grade, and stage of UT-UC) and
final pathologic parameters. Differences in variables with a
continuous distribution across categories were assessed using
the Mann-Whitney 𝑈 test. The Kaplan-Meier method was
used to calculate survival functions, and differences were
assessed with the log rank statistic. Multivariable survival
analyses were performed using the Cox proportional hazard
regression model. Statistical significance in this study was set
as 𝑃 < 0.05. All statistics were completed with SPSS version
21.0 (IBM SPSS Inc., Chicago, IL).
3. Results
Three hundred patients underwent radical nephroureterec-
tomy for upper tract transitional cell carcinoma during the
study period.Themean age of the cohort was 71.82±8.67 yrs
and themajority weremale (60.3%).The baseline characteris-
tics of the cohort are shown in Table 1. 106 (106/300; 35.3%) of
the cohort had PNU using white light, with biopsies taken in
92/106 (86.7%). None of these patients were suspected to have
mucosal changes suggestive of concomitant CIS on PNU.
3.1. Prenephroureterectomy Ureteroscopic Diagnosis of CIS.
Concomitant carcinoma in situ was found in the final
histopathology of nephroureterectomy specimen in 65
(65/300; 21.6%) cases of the cohort (Table 1). Thirty nine
(39/65; 60%) of these patients with CIS on final histopathol-
ogy had white light ureteroscopy. Preureteroscopic voided
urinary cytology was negative for malignant cells in 18 (18/29;
62%) of the concomitant CIS cases.
Concomitant CIS was diagnosed on PNU biopsies in 10
(10/39; 15.3%) patients. Out of these, six did not show CIS
on final histopathology (6/10; 60%). One of these patients
was found to have a single focus of primary CIS on PNU;
however, postresection radical nephroureterectomy showed
no tumour (false positive). PNU failed to suspect or diagnose
CIS in 29 patients (29/39; 84.7%). There were 19 patients
Table 1: Demographic characteristics of the study cohort.
Cohort characteristics Number (%age)
Total number 300
Number with pre nephroureterectomy
ureteroscopy (PNU) 106
Numbers with PNU biopsy 92
Mean age in years (standard deviation) 71.82 ± 8.67
Gender Male 180 (60%)
Female 120 (40%)
Stage
pTa 116 (38.7%)
pT1 83 (27.3%)
pT2 51 (17%)
pT3 49 (16.3%)
Grade
G1/G2 89 (29.6%)
G3 146 (48.6%)
CIS 65 (21.6%)
Multifocal 143 (47.6%)
Urinary bladder recurrences 83 (27.6%)
Contralateral upper tract recurrence 28 (9.3%)
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Figure 1: Overall survival according to presence or absence of CIS
in the upper urinary tract.
in the present study with low grade histology on PNU and
with a subsequent diagnosis of CIS on histopathology of
nephroureterectomy.These patients could have been suitable
for endoscopic management alone based on appearances on
white light ureteroscopy and PNU biopsy. Overall survival
of those with concomitant CIS was significantly lower than
those without (Figure 1; 𝑃 value 0.004).
3.2. Diagnostic Accuracy of PNU Compared to Reference
Standard for Upper Tract Tumours (Table 2 and Figure 2).
Ninety-two patients had PNU biopsies. Only 30 patients
(30/92; 32.6%) had concordance between PNU and final
nephroureterectomy histology for both stage and grade of
disease. Histopathological grading or staging on PNU biopsy
samples was difficult and not possible in 29 patients (29/92;
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Table 2: Histopathological outcomes of patients with prenephroureterectomy ureteroscopic biopsies.
Characteristics
Prenephroureterectomy
biopsy histology
numbers (%age)
Nephroureterectomy
histology∗∗
numbers (%age)
Grade
G1 16 (17.3%) 30 (32.6%)
G2 6 (6.5%) 20 (21.7%)
G3 47 (51.08%) 42 (45.6%)
Stage
pTa 17 (18.4%) 11 (11.9%)
pT1 19 (20.6%) 22 (23.9%)
pT2 4 (4.3%) 39 (42.3%)
pT3 0 20 (21.7%)
Not possible 29 (31.5%) 0
Carcinoma in situ Concomitant CIS 9 (9.7%) 39 (43.3%)
Primary CIS 1 (1.08%) 0
Inconclusive Insufficient material 20 (21.7%) 0
Other reasons 3 (3.2%) 0
∗∗Column contains final results including the inconclusive ureteroscopic biopsies.
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Figure 2: It shows up-/understaging of PNU histology including
outcomes of inconclusive PNU biopsy specimens.
31.5%). Insufficient or poor quality biopsy material remained
the main reason. In the remaining cases of the cohort, PNU
biopsy grade matched with the final histopathology in 40
(40/92; 43.4%) and was both upgraded and downgraded in
11 (11/92; 11.9%) and 11 (11/92; 11.9%) patients, respectively.
Interestingly, being inconclusive or negative for grading on
PNU was reported as high grade tumours subsequently on
postresection nephroureterectomy histology (Figure 2).
PNU failed to accurately stage UT-UCC in half of the
patients. A significant numbers were up staged (36/92; 39.1%)
following nephroureterectomy. Staging was not possible for
29 patients (29/92; 31.5%). Moreover, PNU biopsies did not
do well in those with higher stage disease (T2 and more;
Figure 2).
4. Discussion
Several observations in this study are worth noting. A non-
concordance rate of 45% and 62% for grade and stage between
PNU and final nephroureterectomy histology, respectively, is
much higher than some of the previously reported studies
[18, 19]; however, this is similar to others [14, 15]. The
concordance rate was not better for higher grade tumours
in contrast to the findings of a previous report [20]. In this
large multi-institutional study, PNU significantly underde-
tected concomitant CIS and this remains a major concern.
In part, our inability to obtain precise information about
CIS may explain natural history of higher recurrences and
progression in patients opting for endoscopic management
[21–23]. The incidence of concomitant CIS in the present
study and previous report [9] underscores the importance of
active search for this entity in the upper tract as this may
influence the decision making especially making a choice
between endoscopic nephron sparing and surgical excision
approaches. The rate of CIS varied between 10 and 25%
between the centres; however, it is still lower than some of
the previous reports. False positive and false negative results
of ureteroscopic biopsies have been reported in the previous
studies [14, 24–26]. Our own observation from one (false
positive) in the present study should be kept in mind while
using ureteroscopic biopsy as a tool for selecting patients to
endoscopic or extirpative management, in particularly when
CIS is the only diagnosis on PNU.
In spite of advanced expertise in fibrooptic upper tract
endoscopy, issues with ureteroscopic biopsies such as sub-
optimal tissue volume, poor quality, lack of standardisation
of biopsy technique, and type of preservative for storage of
specimen remain unresolved. Wason et al. [27] described
a better tissue quality yield of ureteroscopically retrieved
biopsy material using BIGopsy forceps in comparison to 3-Fr
ureteroscopic forceps. The specimens were better preserved
and were of sufficient size (31.2mm versus 3.5mm) especially
for sessile and flat lesions. Numbers in the study, however,
were small and tissue samples obtained fromnephroureterec-
tomy specimenwere in an ex vivo setting. Recently Ritter et al.
[28] have reported a lower field of viewusing BIGopsy forceps
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again in ex vivo settings. Other factors such as irrigation
flow and deflectability of endoscopes need to be kept in
mind for flexible ureteroscopic and particularly in areas of
relatively difficult access. This may explain a large variation
which exists in quality of tissue obtained from renal pelvis
and ureters as former site is difficult to approach. Whether
insertion of ureteral access sheath improves acquisition of
better quality tissue as suggested by Gorin et al. [29] needs
further study. The quality of tissue retrieved should be a
denominator for any technological improvement.The largest
samples obtained may not be necessarily of a good quality as
they may suffer from lack of architectural preservation due
to urothelial denudation [29]. Bultitude et al. [30] suggested
use of Bouin’s fixative method for preservation of nuclear
details of the tissue samples obtained ureteroscopically. The
method may be useful for determining the grade of tumour;
however, its role in reducing the discordance rate as seen in
the present needs further assessment. Obtaining good quality
tissue samples from flat and sessile lesions such as CIS poses
a difficult challenge in a relatively narrow structure such as
ureter. A deeper bite may lead to perforation or higher risk of
tumour cell seeding especially in high grade lesions.
Presence of carcinoma in situ is known to be a poor
prognosticmarker for urinary bladder cancer; however, there
are no studies to assess reliability of PNU in diagnosing this
entity in the upper tract. Interestingly, if not surprisingly,
none of the concomitant upper tract carcinoma in situ lesions
as confirmed on histopathology of nephroureterectomy spec-
imen was suspected or diagnosed on PNU. The majority
of patients with concomitant CIS had high grade UT-UCC,
higher follow-up recurrences, and poor outcome.There were
19 patients in the present study with low grade histology
on PNU histology and with a subsequent diagnosis of CIS
on histopathology of nephroureterectomy. Potentially, these
patients could have been offered endoscopic management
and CIS would have been missed. With a low concordance
rate for grading and missing of CIS on PNU, proper selec-
tion of patients with UT-UCC for endoscopic management
becomes a real issue. Additional information from urinary
cytology did not improve diagnostic precision in the present
study. The role of other urinary biomarkers in conjunction
with white light ureteroscopy for the diagnosis of upper tract
TCC needs future research. New endoscopic developments
such as photodynamic diagnosis [16, 31], narrow band imag-
ing [32], and optical coherence tomography [33] are emerging
to address the issue of poor ureteroscopic retrieval of tissues.
The diagnostic accuracy of these emerging imaging tech-
niques needs to be assessed using proper gold standard such
as final histopathology from nephroureterectomy specimen.
These techniques may become part of eNSS approach for
upper tract TCC in the future.
We have used a large multi-institutional data with val-
idation of part of the cohort by electronic cross-linkage
methodology as described previously [34, 35]. Although
all the centres have a strong interest in and experience of
endoscopic diagnosis of upper tract urothelial cancers, lack
of randomisation to PNU, no PNU biopsies from normal
appearing ureters to confirm diagnosis of CIS prior to
nephroureterectomy, lack of information onwhether CIS was
de nova or concomitant, and a small number of patients with
CIS on PNU are some of limitations of the present study.
The data from present study, however, should encourage
reporting and active search to rule out CIS in patients opting
for endoscopic management. How best we can achieve this
remains a topic of future research and discussions. Further-
more, large tumours obvious onCTurography and thosewith
tightmalignant ureteric stricturesmay not have gone through
diagnostic ureteroscopy route and this induces a selection
bias in the present study. A further limitation of the findings
from the present study could be the possibility that different
instruments were used in multi-institutional/multisurgeon
nature of the PNU biopsy procedure. Given a high expertise
is needed to obtain reliable biopsy tissue in PNU, this may be
another source of bias in the present study.
A number of areas of future research in the management
of upper tract TCC come under sharp focus in the light of
findings of the present study.
(1) Prospective protocol driven studies with robust ref-
erence standards are urgently needed to assess the
diagnostic accuracy of PNU in selecting low grade
patients for endoscopic nephron sparing approach.
(2) Technological advancements especially role of pho-
todynamic diagnosis and optical coherence tomog-
raphy need to be assessed in prospective multicentre
studies.
(3) A consensus on the quality of ureteroscopically re-
trieved biopsy material including methods of preser-
vation needs to be reached through cross-disciplinary
approach.
(4) Due to relative rare nature of these tumours, a mul-
ticentre international collaborative group with focus
on key questions both in research and clinical need to
be established.
5. Conclusions
There is a high incidence of CIS in upper tract with sig-
nificant underdetection and discordance rate between the
histopathology of biopsy samples obtained by white light
PNU and resected specimen of radical nephroureterectomy,
in particularly for the presence of CIS. The presence of con-
comitant CIS and high stage disease in the upper tract TCC
carried a poor prognosis following radical nephroureterec-
tomy.
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